{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kroon J"],"funding":["NanoNextNL Drug Delivery programme 03D.01","the Netherlands Organisation","European Research Council","Dutch Cancer Society","PRONET"],"pagination":["815-24"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5006873"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["75(8)"],"pubmed_abstract":["Background
The inflammatory tumor microenvironment, and more specifically the tumor-associated macrophages, plays an essential role in the development and progression of prostate cancer towards metastatic bone disease. Tumors are often characterized by a leaky vasculature, which - combined with the prolonged circulation kinetics of liposomes - leads to efficient tumor localization of these drug carriers, via the so-called enhanced permeability and retention (EPR) -effect. In this study, we evaluated the utility of targeted, liposomal drug delivery of the glucocorticoid dexamethasone in a model of prostate cancer bone metastases.Methods
Tumor-bearing Balb-c nu/nu mice were treated intravenously with 0.2-1.0-5.0 mg/kg/week free- and liposomal DEX for 3-4 weeks and tumor growt"],"journal":["The Prostate"],"pubmed_title":["Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo."],"pmcid":["PMC5006873"],"funding_grant_id":["UL-2011-4030","309494","916.131.10","309494:NeoNaNo"],"pubmed_authors":["van Bloois L","Cheung H","van der Horst G","Buijs JT","Pelger RC","Storm G","Metselaar JM","Lammers T","van der Pluijm G","van der Mark M","Kroon J","Rizzo LY"],"additional_accession":[]},"is_claimable":false,"name":"Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.","description":"Background
The inflammatory tumor microenvironment, and more specifically the tumor-associated macrophages, plays an essential role in the development and progression of prostate cancer towards metastatic bone disease. Tumors are often characterized by a leaky vasculature, which - combined with the prolonged circulation kinetics of liposomes - leads to efficient tumor localization of these drug carriers, via the so-called enhanced permeability and retention (EPR) -effect. In this study, we evaluated the utility of targeted, liposomal drug delivery of the glucocorticoid dexamethasone in a model of prostate cancer bone metastases.Methods
Tumor-bearing Balb-c nu/nu mice were treated intravenously with 0.2-1.0-5.0 mg/kg/week free- and liposomal DEX for 3-4 weeks and tumor growt","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jun","modification":"2026-03-16T15:57:56.242Z","creation":"2025-08-28T03:08:55.153Z"},"accession":"S-EPMC5006873","cross_references":{"pubmed":["25663076"],"doi":["10.1002/pros.22963"]}}